Tempus AI (TEM) – Analysts’ Recent Ratings Changes

Posted by on Jun 18th, 2026

Tempus AI (NASDAQ: TEM) has recently received a number of price target changes and ratings updates:

  • 6/6/2026 – Tempus AI was upgraded by Wall Street Zen from “sell” to “hold”.
  • 6/2/2026 – Tempus AI is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
  • 6/1/2026 – Tempus AI had its “buy” rating reaffirmed by BTIG Research. They now have a $80.00 price target on the stock.
  • 6/1/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
  • 5/11/2026 – Tempus AI had its price target lowered by HC Wainwright from $95.00 to $64.00. They now have a “buy” rating on the stock.
  • 5/8/2026 – Tempus AI had its price target lowered by BTIG Research from $90.00 to $80.00. They now have a “buy” rating on the stock.
  • 5/6/2026 – Tempus AI had its price target raised by TD Cowen from $65.00 to $68.00. They now have a “buy” rating on the stock.

Insider Activity

In other Tempus AI news, EVP Andrew Polovin sold 8,703 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the transaction, the executive vice president directly owned 128,215 shares of the company’s stock, valued at $5,650,435.05. The trade was a 6.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 10,853 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $478,291.71. Following the completion of the transaction, the chief financial officer owned 126,395 shares of the company’s stock, valued at $5,570,227.65. This represents a 7.91% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 558,557 shares of company stock worth $26,611,939 in the last quarter. Insiders own 24.26% of the company’s stock.

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Further Reading

Receive News & Ratings for Tempus AI Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI Inc and related companies with MarketBeat.com's FREE daily email newsletter.